- Tytuł:
- Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet 18-24 November 2023 402(10415):1835-1847
Czasopismo naukowe